Candriam Luxembourg S.C.A. Sells 40,000 Shares of Catalyst Pharmaceuticals, Inc. (CPRX)

Candriam Luxembourg S.C.A. reduced its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 6.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 560,000 shares of the biopharmaceutical company’s stock after selling 40,000 shares during the period. Candriam Luxembourg S.C.A. owned about 0.67% of Catalyst Pharmaceuticals worth $1,546,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Oxford Asset Management raised its position in Catalyst Pharmaceuticals by 138.1% in the first quarter. Oxford Asset Management now owns 58,940 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 34,181 shares during the last quarter. Bank of New York Mellon Corp raised its position in Catalyst Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 2,404 shares during the last quarter. JPMorgan Chase & Co. bought a new position in Catalyst Pharmaceuticals during the first quarter valued at approximately $155,000. Knott David M bought a new position in Catalyst Pharmaceuticals during the first quarter valued at approximately $554,000. Finally, Renaissance Technologies LLC bought a new position in Catalyst Pharmaceuticals during the first quarter valued at approximately $746,000. 29.79% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals, Inc. (CPRX) opened at 2.72 on Friday. The stock has a 50 day moving average price of $2.88 and a 200 day moving average price of $1.98. Catalyst Pharmaceuticals, Inc. has a 52-week low of $0.74 and a 52-week high of $3.20. The company’s market capitalization is $228.22 million.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. On average, equities analysts expect that Catalyst Pharmaceuticals, Inc. will post ($0.25) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by [[site]] and is the property of of [[site]]. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at [[permalink]].

Several research analysts have recently commented on the company. Roth Capital set a $5.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday. Piper Jaffray Companies set a $6.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, August 7th. Finally, Zacks Investment Research lowered Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.